| Identification | Back Directory | [Name]
Lipid N2-3L | [CAS]
2924606-55-1 | [Synonyms]
Lipid N2-3L
9-Octadecenoic acid (9Z)-, 3-[2-[(2-hexyl-1-oxodecyl)oxy]ethyl]-14-hydroxy-12-(2-hydroxyethyl)-7-oxo-6-oxa-3,8,12-triazatetradec-1-yl ester | [Molecular Formula]
C48H93N3O8 | [MOL File]
2924606-55-1.mol | [Molecular Weight]
840.27 |
| Chemical Properties | Back Directory | [Boiling point ]
838.859±65.00 °C(Press: 760.00 Torr)(predicted) | [density ]
0.996±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [solubility ]
DMSO: Soluble: =10 mg/ml
Ethanol: Soluble: =10 mg/ml | [pka]
12.650±0.46(predicted) |
| Hazard Information | Back Directory | [Description]
Lipid N2-3L is an ionizable cationic lipid (pKa = 8.99) that has been used in the generation of supramolecular lipid nanoparticles (SMLNPs) encapsulating mRNA for use in vitro and in vivo.1 SMLNPs containing lipid N2-3L and encapsulating a luciferase reporter accumulate at the site of injection and in the draining lymph nodes of mice. Lipid N2-3L-containing SMLNPs encapsulating ovalbumin mRNA and the toll-like receptor 7/8 (TLR7/8) agonist R-848 (Item No. 14806) as an adjuvant promote dendritic cell maturation and antigen presentation, reduce tumor volume, and increase survival in an MC-38-OVA murine model of colon cancer.WARNING This product is not for human or veterinary use. | [References]
[1] SHAOLONG QI. Supramolecular Lipid Nanoparticles Based on Host–Guest Recognition: A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy[J]. Advanced Materials, 2024, 36 23. DOI: 10.1002/adma.202311574 |
|
|